Clinical trial
Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome.
NCT00603109 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome.
- Lead sponsor
- Weill Medical College of Cornell University
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 31, 2007
- Completion date
- January 31, 2009
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.